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Acute oral, dermal and inhalation toxicity classiﬁcations of chemicals under the United Nations Globally
Harmonized System of Classiﬁcation and Labelling of Chemicals (GHS) should typically be based on data
from rats and rabbits, with the tacit assumption that such characterizations are valid for human risk.
However this assumption is not appropriate in all cases. A case in point is the acute toxicity classiﬁcation
of ethylene glycol mono-n-butyl ether (EGBE, 2-butoxyethanol, CAS 111-76-2), where acute toxicity data
from rats or rabbits leads to an overly conservative assessment of toxicity. Hemolysis is the primary
response elicited in sensitive species following EGBE administration and the proximate toxicant in this
response is 2-butoxyacetic acid (BAA), the major metabolite of EGBE. The sensitivity of erythrocytes to
this effect varies between species; rats and rabbits are sensitive to BAA-mediated hemolysis, whereas
humans and guinea pigs are not. In this publication, a weight of evidence approach for the acute hazard
classiﬁcation of EGBE under GHS is presented. The approach uses acute toxicity data from guinea pigs
with supporting mechanistic and pharmacokinetic data in conjunction with human experience and
shows that adopting the standard method results in over-classiﬁcation.
 2013 The Authors. Published by Elsevier Inc.Open access under CC BY license.1. Introduction
Ethylene glycol mono-n-butyl ether (EGBE, CAS No. 111-76-2) is
a high production volume glycol ether solvent and is a component
of a variety of products including hydraulic brake ﬂuids, water-
based coatings, and hard-surface cleaners (Boatman and Knaak,
2001). The hazards and risks associated with this solvent have
been extensively reviewed (Boatman and Knaak, 2001; ECETOC,
2004; ECHA, 2010; EPA, 2010; IARC, 2006; WHO, 1998). Currently
the harmonized hazardous substance classiﬁcation for acute toxic-
ity in the European Union for EGBE under the Dangerous Substance
Directive (67/548/EEC) is Xn: R20/21/22 (harmful by inhalation, in
contact with skin and if swallowed). This corresponds with the
translated harmonized hazardous substance classiﬁcation for acute
toxicity of EGBE under Regulation (EC) No. 1272/2008 (Annex VI)
which is Acute Toxicity Category 4 (‘harmful’) for oral, dermal
and inhalation exposures. The Globally Harmonized System
(GHS) classiﬁcations taken from the Dangerous Substances Direc-tive represent the equivalent categories and do not take into ac-
count the different classiﬁcation thresholds.
In early studies in rodents and rabbits, it was recognized that
EGBE produces a hemolytic response characterized by the appear-
ance of hemoglobinuria and by changes in a variety of blood
parameters (Werner et al., 1943; Carpenter et al., 1956). Although
ﬁrst recognized following inhalation exposures, such effects are
also present following oral and dermal administrations (Carpenter
et al., 1956; Grant et al., 1985; Bartnik et al., 1987). Hemolysis is
observed following both single and repeated exposures to EGBE,
with apparent tolerance to EGBE-induced hemolysis developing
in sub-acute or sub-chronic studies (Krasavage, 1986; Grant
et al., 1985). Ghanayem et al. (1990) have shown that this toler-
ance to hemolysis is a consequence of the replacement of older
and more susceptible erythrocytes with less susceptible, younger
cells. Other reports have subsequently conﬁrmed these ﬁndings
(Sivarao and Mehendale, 1995).
The acute toxicity of EGBE varies among test species, but would
generally be classiﬁed as low to moderate. Acute signs of toxicity in
sensitive experimental animals include lethargy, labored breathing
and ataxia, generally accompanied by clear evidence of hemolysis
(Boatman and Knaak, 2001; ECETOC, 2004; ECHA, 2010). Patholog-
ical effects often noted in these acute studies and that are consid-
ered to be secondary to hemolysis may include hemorrhagic lungs,
mottled livers, congested kidneys and spleens, red-stained ﬂuid in
Table 1
Acute toxicity hazard categories and acute toxicity estimated cut-off values for oral, dermal and inhalation exposures according to the Globally Harmonized System of
Classiﬁcation and Labeling of Chemicals (GHS).
Exposure route Category 1 Category 2 Category 3 Category 4 Category 5
Oral (mg/kg bw)a 5 50 300 2000 5000
Dermal (mg/kg bw)a 50 200 1000 2000 5000
Vapors (mg/l)a 0.5 2.0 10 20 Note 1
Note 1: No speciﬁc cut-off value is assigned for acute vapor inhalation for Category 5. A dose equivalent to a 2000–5000 mg/kg bw exposure from an oral or dermal exposures
is speciﬁed.
a Acute toxicity estimates are derived from LD50/LC50 values from animal studies where available.
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Hematuria was often observed in animals that died or were seri-
ously affected. In reliable studies1 reviewed under the European Un-
ion REACH registration process (ECHA, 2010), LD50 values from acute
oral toxicity studies in experimental animals ranged from 615 mg/
kg bw to values in excess of 2000 mg/kg bw; LD50 values from acute
dermal toxicity studies ranged from 435 mg/kg bw to values in ex-
cess of 2000 mg/kg bw; and LC50 values from inhalation studies ran-
ged from ca. 400 ppm (2.0 mg/L, 7 h exposure) to values in excess of
3.9 mg/L (theoretical maximum achievable concentration).
The acute toxicity database for EGBE indicates the guinea pig to
be relatively insensitive to the hemolytic effects that are observed
in other sensitive species (Gingell et al., 1998; Boatman and Knaak,
2001; ECHA, 2010). This is reﬂected in generally low levels of acute
toxicity in this species. In reliable studies conducted using the gui-
nea pig, a LD50 value from an acute oral toxicity study of 1414 mg/
kg bw has been reported; LD50 values from acute dermal toxicity
studies in excess of 2000 mg/kg bw have been reported; and LC50
values from inhalation studies of approximately 400 ppm
(2.0 mg/L) for a 7 h exposure, as well as values in excess of the
maximum achievable vapor concentration of 633 ppm (3.1 mg/L)
or 691 ppm (3.4 mg/l) for 1-h exposures have been reported. As
in the case of the guinea pig, humans are generally insensitive to
the hemolytic toxicity of EGBE. Under conditions of controlled hu-
man exposures, no overt toxicity or signs of hemolytic effects have
been observed (Carpenter et al., 1956; Johanson, 1986; Johanson
and Boman, 1991). In well-documented cases of intentional inges-
tions of large amounts of EGBE-containing products, coma with
respiratory and other complications has been reported, but with
little conclusive evidence of hemolysis (reviewed in Udden,
1996; Gualtieri et al., 2003; Hung et al., 2010). Metabolic acidosis
is the critical effect observed in these poisonings with survival of
all individuals following appropriate supportive care.
Under the guidelines for classiﬁcation of acute toxicity accord-
ing to GHS, the rat is the preferred species for evaluation of acute
oral and inhalation toxicity and the rabbit the preferred species
for acute dermal toxicity. Strictly applying the classiﬁcation
thresholds of this guideline may result in possible classiﬁcations
for EGBE of Acute Toxicity Category 3 for both dermal and inhala-
tion exposures (H311, toxic if in contact with skin; H331, toxic if
inhaled). Such classiﬁcations are overly conservative and do not
represent actual hazard from human exposure. This review pro-
vides evidence for the use of acute toxicity data from the guinea
pig as being most appropriate for setting acute toxicity hazard clas-
siﬁcations for EGBE.
2. Overview of acute toxicity classiﬁcation under GHS
2.1. Hazard categories and guidance criteria for acute toxicity
classiﬁcation under GHS
For the purposes of classiﬁcation, acute toxicity is deﬁned as an
adverse effect occurring following a single oral or dermal dose of a1 Reliability was assessed according to Klimisch et al. (1997).chemical. An adverse effect resulting from multiple doses adminis-
tered within 24 h would also be considered an acute effect. An
acute inhalation effect is deﬁned as an adverse response following
a 4-h exposure. The allocation of substances to one of ﬁve toxicity
categories under GHS is shown in Table 1. The values shown repre-
sent numeric cut-off values for each category.
The general guidance provided for classiﬁcations under the GHS
classiﬁcation system as well as the related classiﬁcations under
Regulation (EC) No. 1272/2008 (Classiﬁcation, Labelling and Pack-
aging (CLP) of substances and mixtures) recognize that animal data
from acute toxicity studies will generally provide the acute toxicity
estimates (ATE) as indicated by the cut-off values in Table 1.
Although presented as estimates, in fact and in common practice,
these default values become ipso facto the required values for clas-
siﬁcation. In other words, if reliable animal test data is available,
and in the absence of reliable or contradictory human data, the val-
ues in Table 1 represent the default values for classiﬁcation. As sta-
ted in the guidance for GHS classiﬁcation system (UN, 2011), the
rat is the preferred test species for acute oral and inhalation expo-
sures. Thus, acute oral LD50 values from reliable studies in rats have
precedence over other acute toxicity data from experimental ani-
mals. Similarly, acute inhalation 4-h LC50 values from studies con-
ducted in rats are the preferred value for setting the acute
inhalation classiﬁcation. Acute toxicity data from either the rat or
rabbit is preferred for evaluation of dermal toxicity. However the
GHS text (and the CLP legal text) also state that when experimental
data for acute toxicity are available in several animal species, sci-
entiﬁc judgement should be used in selecting the most appropriate
LD50 value from among valid, well-performed tests. Therefore,
when determining the acute toxicity of a substance, it is acceptable
to deviate from the standard species (rats and rabbits) where there
is a sound scientiﬁc basis for doing so.
2.2. Use of human data for hazard classiﬁcation under GHS
It is clearly stated in the GHS guidance that the protection of hu-
man health and the environment is a primary goal of the harmo-
nized hazard classiﬁcation scheme. For the purpose of acute
toxicity classiﬁcation, reliable epidemiological data as well as
experience gained from occupational exposures, medical surveil-
lance, case reports or reports from national poison centers are all
recognized sources of information. A weight of evidence approach
is to be used for classiﬁcation, with both human and animal data
considered. In cases of a conﬂict, the quality and reliability of the
results evaluated must be assessed to determine the ﬁnal classiﬁ-
cation. Expert judgment must be applied for weight of evidence
determinations both to assess quality and reliability as well as to
assess confounding factors.
3. Summary of acute toxicity data for EGBE
Summarized in Tables 2–4 are acute toxicity data for EGBE from
experimental animals following oral, dermal or inhalation expo-
sures. The studies listed have been reviewed for reliability under
the requirements of the EU REACH registration program and most
Table 2
Acute oral toxicity values for EGBE.
Route/species/strain/
sex/age
Dose Exposure regime Results (mg/kg bw)/evidence of hemolysis Referencesa
Rat/COBS CD BR/male 2.6–168 mM/kg bw
(5 dose levels)
Gavage (no vehicle)
fasted and fed
animals
LD50 = 1746 (fasted and fed animals)/hematuria; blood in stomach
and intestines
Krasavage and
Terhaar (1981a)
Rat/male–female 200, 400, 500, 640,
800, 1000, 1250 and
1600 mg/kg bw
Gavage (water
vehicle)
LD50 = 880 (male) LD50 = 615 (female)/hemolytic urine; anemic
musculature; hemoglobinuric nephrosis
BASF AG (1968)
Rat/Wistar/male/ No data on doses
administered
Gavage (water) LD50 = 1480/effects in Kidney and liver Smyth et al.
(1941)
Rat/Sherman and
Carworth/male–
female/5–6 weeks of
age
No data on doses
administered
Gavage (undiluted
or in water) 5% or
10% dilutions
LD50 (range-8 studies) >560 to <3000 (male) LD50 = 2100 (male) LD50
(range-6 studies) >530 to <2800 (female) LD50 = 1850 (female)/
hemoglobinuria; hemorrhaged lungs; mottled livers; congested
kidneys
Carpenter et al.
(1956), Dow
(1952)
Rat/CDF (F344 derived)/
female
130, 250, 500, 1000
and 2000 mg/kg bw
Gavage (no vehicle) LD50 >1000 to <2000 (est. 1900)/staining of perianal region; necrosis
of tails
Dow (1981)
Rat/Wistar/male/ 1128, 2257, 4515 and
9030 mg/kg bw
Gavage (no data on
vehicle)
LD50 = 2420/bloody salivation; dark livers; distended stomachs ﬁlled
with liquid and gas; red colored kidneys and adrenals; blood in
intestines
DOW (1980a)
Mouse/CD-1/male 2.6–168 mM/kg bw (5
dose levels)
GAVAGE (no vehicle)
fasted and fed
animals
LD50 = 1519 (fasted) LD50 = 2005 (fed)/hematuria; blood in stomach
and intestines
Krasavage and
Terhaar (1981a)
Mouse/male No data on doses
administered
Gavage (water) LD50 = 1230 Carpenter et al.
(1956)b
Rabbit/male No data on doses
administered
Gavage (water) LD50 = 320 and 370 mg/kg bw (2 studies) Carpenter et al.
(1956)c
Rabbit/male–female Approx. 695 and
1400 mg/kg bw
Gavage (water) LD100 = 695/hemoglobinuric nephrosis; bloody-red coloration in
anterior chamber of eyes; decreased hematocrits; degenerative blood
changes; lung edema
BASF AG (1967)
Dog/beagle/male–
female
Approx. 695 mg/kg bw Gavage (water) LD50 > 695/no abnormalities noted BASF AG (1966)
Guinea pig/Hartley/
male–female/5–
7 weeks of age
500, 1000 and
2000 mg/kg bw
Gavage (distilled
water) dose volume
1.5–2.0 ml
LD50 = 1414/no evidence of hemolysis Shepard (1994a),
Gingell et al.
(1998)
Guinea pig/male–
female
No data on doses
administered
Gavage (water) LD50 = 1200/no evidence of hemolysis Smyth et al.
(1941), Carpenter
et al. (1956)
a Unless otherwise noted, studies summarized were judged to have reliabilities of 1 or 2 using the scale and scoring system of Klimisch et al. (1997).
b A reliability rating of Klimisch 4 was assigned to this study. However, the results have been included as supporting information.
c Although judged of low reliability, this study has been included as supporting information.
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3.1. Acute oral toxicity of EGBE in experimental animals
Table 2 lists acute toxicity data from experimental animals ex-
posed by the oral route to EGBE. Acute oral toxicity has been most
commonly measured in young adult rats, with reported LD50 val-
ues varying signiﬁcantly over a range of 615 mg/kg bw (BASF AG,
1968) to 2100 mg/kg bw (Carpenter et al., 1956). Hemolysis was
observed in the majority of these studies, sometimes accompanied
with renal and hepatic lesions, presumed to be a consequence of
hemolysis. In animals dying prior to study terminations, patholog-
ical effects often noted included bloody urine and/or blood in the
stomach and intestines and diffuse necrosis and hemorrhage of
the gastric mucosa, indicative of a gastric irritant.
In a single reliable acute oral toxicity study conducted in mice,
both fasted and fed male mice were treated by gavage with undi-
luted EGBE (Krasavage and Terhaar, 1981a). Fasted mice appeared
somewhat more sensitive to EGBE than fed mice with LD50 values
of 1519 mg/kg bw (fasted) versus 2005 mg/kg bw (fed).
In two older and less reliable acute oral toxicity studies by
Carpenter et al. (1956), rabbits were reported to be the most sen-
sitive of the species tested that included rats, mice, and guinea
pigs. The LD50 values reported in these studies were 320–
370 mg/kg bw. These values seem low compared with those of
other species but are consistent with more recent data for this spe-cies indicating complete mortality in both male and female rabbits
at an administered dose of 695 mg/kg bw (BASF AG, 1967).
Two reviewed studies are available in guinea-pigs, one of which
is a more recent GLP guideline study. The LD50 values reported in
these studies, 1414 and 1200 mg/kg bw, were comparable
(Shepard, 1994a (as reviewed by Gingell et al., 1998); Carpenter
et al., 1956). The same or similar clinical signs and pathology as
displayed in other species were seen in these studies. However,
in the more recent study of Shepard (1994a), there was no evi-
dence of hemolysis or any effects noted on erythrocytes. Gastroin-
testinal irritation, as evidenced by sialorrhea and changes in the
gastric mucosa, may have contributed to the toxicity in this study.
3.2. Acute dermal toxicity of EGBE in experimental animals
Listed in Table 3 are acute dermal toxicity data for EGBE in
experimental animals. In most cases, experimental conditions in-
cluded occlusive exposures of 24-h duration. Data is presented
for three species: the rat, rabbit and guinea pig.
In male and female rats, both occlusive and semi-occlusive
exposures to undiluted EGBE are available and, using a weight of
evidence approach, the LD50 value in the rat can be considered to
be >2000 mg/kg bw both under occluded and non-occluded condi-
tions (Table 3). In rabbits, the results shown in Table 3 are gener-
ally consistent and indicate an increased acute dermal toxicity of
EGBE in this species. In guinea-pigs, variations in LD50 values were
seen among the studies with a range from 230 mg/kg bw to
Table 3
Acute dermal toxicity values for EGBE.
Route/species/strain/sex/age Dose Exposure regime Results (mg/kg bw)/evidence of hemolysis Referencesa
Rat/Spague–Dawley/male–
female/10–14 weeks of age
2000 mg/kg bw Semi-occlusive or
occlusive/no vehicle/
24 h exposure
LD50 > 2000 (semi-occlusive) LD50 > 2000 (occlusive)/under
occlusive conditions only: pallor; red/brown staining around
eyes; hemorrhagic lungs; dark livers and kidneys;
hemorrhage of small and large intestines
Allen (1993a)
Rat No data Occlusive/4 h
exposure
LD50 = 2275 DOW (1961)
Rabbit/New Zealand White/
male–female/12–20 weeks
of age
500, 707 and 1000 mg/
kg bw (occlusive)
1200 mg/kg bw (semi-
occlusive)
Semi-occlusive or
occlusive/no vehicle/
24 h exposure
Occlusive: LD50 (male/female) = 841
LD50 (male) = 1060
LD50 (female) = 667 semi-occlusive: LD50 > 2000/under
occlusive conditions: red-stained urine; hemorrhagic lungs;
dark livers and kidneys; red ﬂuid in bladders; hemorrhage of
gastric mucosa and small and large intestines (effects
lessened under semi-occlusion)
Allen (1993b)
Rabbit//male–female 3 doses/not speciﬁed Occlusive/no vehicle/
24 h exposure
LD50 = 612 Roudabush
et al. (1964)
Rabbit/New Zealand White/
male
153, 307, 614 and
1239 mg/kg bw
Occlusive/no vehicle/
24 h exposure
LD50 = 435/discoloration of liver, kidneys, stomachs and
small intestines; red/brown ﬂuid in urinary bladders
Krasavage
and Terhaar
(1981b)
Rabbit/New Zealand White/
male
Single dose in most
experiments
Occlusive/no vehicle/
24 h exposure
LD50 = 450 and 560 mg/kg bw/hemoglobinuria; blood in
urine; pale livers; engorged spleens
Carpenter
et al. (1956)
Rabbit/New Zealand White/
male/age 3–5 months
0.5 and 1.0 ml/kg bw Occlusive/no vehicle LD50 = 567/blood in urine; orange/red lungs and livers; dark
kidneys and spleens; red peritonea and orange intestines
DOW (1980a)
Guinea pig/Hartley/male–
female/6–7 weeks of age
(female); 5–6 weeks of age
(male)
2000 mg/kg bw Occlusive/no vehicle/
24 h exposure/
washing following
exposure
LD50 > 2000/no treatment-related changes Shepard
(1994b),
Gingell et al.
(1998)
Guinea pig/Hartly/male 3 doses/not speciﬁed Occlusive/abraded and
intact skin/24 h
exposure
LD50 = 207 (intact) LD50 = 270 (abraded) Roudabush
et al. (1964)
Guinea pig 2, 5, 6, 8 and 10 ml/kg bw Occlusive/no vehicle/
4 day exposure
LD50 = 6550 (corrected for density) DOW (1938)
Guinea pig 1.2 and 4.8 g/kg bw Skin depot left in place
until all material
absorbed
LD50 > 1200 mg/kg bw Wahlberg
and Boman
(1979)
a Unless otherwise noted, studies summarized were judged to have reliabilities of 1 or 2 using the scale and scoring system of Klimisch et al. (1997).
44 R. Boatman et al. / Regulatory Toxicology and Pharmacology 68 (2014) 41–50>2000 mg/kg bw. An older study reported by Roudabush et al.
(1964) indicates a much higher dermal toxicity than more recently
reported studies. In particular, the more recent guideline study of
Shepard (1994b) reports a LD50 value of greater than 2000 mg/
kg bw. In this study, no adverse effects were described (local or
systemic). The value reported by Shepard (1994b; as reviewed by
Gingell et al., 1998) is consistent with the value of >1200 mg/kg bw
reported by Wahlberg and Boman (1979).3.3. Acute inhalation toxicity of EGBE in experimental animals
Listed in Table 4 are acute inhalation toxicity data for EGBE in
experimental animals. Exposure durations reported in these stud-
ies ranged from 1 to 8 h thus complicating a direct comparison of
the study results. No attempt has been made to correct for expo-
sure durations. When interpreting the ﬁndings from these inhala-
tion studies, it is also important to note that the calculated
saturated vapor concentration of EGBE under ambient conditions
is 791 ppm (3.9 mg/l) (DOW, 1974). Thus values in excess of this
may represent nominal values. Maximummeasured achievable va-
por concentrations below this have been reported (DOW, 1994).
The acute inhalation toxicity of EGBE has been most commonly
measured in the rat. Acute 4-h inhalation LC50 values in male and
female rats were 2.4 and 2.2 mg/l, respectively (DOW, 1980b). LC50
values at or near the theoretical maximum vapor concentration
have been reported for exposure durations from 1 to 8 h
(MacDonald, 1982; Carpenter et al., 1956). There is some limited
evidence to suggest that female rats are more sensitive than males
(DOW, 1980b; MacDonald, 1982). Clinical signs and pathology
indicative of hemolytic toxicity are seen.In six, 7-h exposure studies in male rabbits at approximate va-
por concentrations of 400 ppm (2.0 mg/l), an LC50 of 400 ppm
(2.0 mg/l) was reported representing a mortality rate of 10/24 ani-
mals as an aggregate of the six studies (DOW, 1974).
In a more recent and well-documented acute inhalation toxicity
study in male and female guinea pigs, test animals were exposed to
maximum achievable vapor concentrations of EGBE for 1 h (DOW,
1994; Gingell et al., 1998). There was neither mortality nor adverse
clinical effects noted in this study. There were also no signiﬁcant
adverse pathological effects reported. The LC0 values for guinea
pigs in this latter study were 3.1 mg/l (females) and 3.4 mg/l
(males), representing the maximum measured vapor concentra-
tions achieved in the study. It is worth noting that at a theoretical
maximum saturated vapor concentration of 3.9 mg/l, and given a
standard respiratory minute volume in the guinea pig of 0.66
l/min/kg bw (Snipes, 1988), a 4 h inhalation exposure in a guinea
pig would result in an internal dose (assuming 100% absorption)
of 618 mg/kg bw, which is approximately half of the acute oral
LD50 value in this species. Thus at experimentally-achievable vapor
concentrations, a LC50 value from a 4-h exposure cannot be ob-
tained in this species.
4. Human exposure data for EGBE relevant to an acute hazard
classiﬁcation
4.1. Controlled exposures of volunteers to EGBE
No evidence for hemolysis has been reported in any controlled
laboratory exposures of human volunteers to EGBE by inhalation.
In early studies by Carpenter et al. (1956), there was neither in-
creased osmotic fragility of erythrocytes nor other signs of hemo-
Table 4
Acute inhalation toxicity values for EGBE.
Route/species/strain/sex/
age
Dose Exposure
regime
Results (mg/l)a/evidence of hemolysis Referencesb
Rat/Fischer 344/male–
female/6–7 weeks of
age
867, 523 and 202 ppm
(measured)
4-h exposure/
whole body
LC50 = 2.4 (males) LC50 = 2.2 (females)/red ﬂuid discharge around
urogenital region; enlarged and discolored kidneys; red-stained urine
in bladders
DOW (1980b)
Rat/Wistar/male–female/
8 weeks of age
900–910 ppm >1 to <7 h/
three studies
LC50  4.4 (females) LC50 > 4.4 (males)/blood in urine; necrosis of
tails; pale eyes and feet
MacDonald
(1982)
Rat/male–female 1.44 mg/l (3 h) 4.25 mg/l
(8 h)
3 or 8 h
exposures/
whole body
LC0 = 1.44 (3 h, no deaths) LC100 = 4.25 (8 h, complete mortality)/
hematuria; slight anemia; liver anemia; blood clotting in bladders
BASF AG (1968)
Rat/Sprague–Dawley/
male–female
2.25 mg/l (3 h), 4.26 mg/l
(7 h)
3 or 7 h
exposures/
whole body
LC50 > 4.26/hemorrhagic urine; anemic ears; discolored liver; bloody
ulcerations of the glandular stomach
BASF AG (1979)
Rat/male–female 4.9 mg/l (measured) >1 to <3 h LC0 > 4.9 mg/L (3 h) Klimisch et al.
(1988)
Rat/female (also, older
animals studiedO
500 and 800 ppm P4 to 68 h LC50 = 3.9 (4 h)
LC50  3.9 (8 h)/hemoglobinuria
Carpenter et al.
(1956)
Rabbit/male 403 ppm (average) 7 h/whole
body
LC50  2.0/hematuria; reddish ocular and nasal discharges;
discoloration of sclera of eyes; severely congested kidneys; mottled
livers
DOW (1974)
Dog/Beagle/male 403 ppm (average) 7 h/whole
body
LC0 > 2.0 mg/l/no signs of hemolysis DOW (1974)
Guinea pig/Dunkin–
Hartley/males–females/
36 days of age
633 ppm (measured,
females) 691 ppm
(measured, males)
1 h/whole
body
LC0 > 3.1 (females)
LC0 > 3.4 (males)/no adverse clinical ﬁndings
DOW (1994),
Gingell et al.
(1998)
Guinea pig/male 403 ppm (average) 7 h/whole
body
LC0 > 2.0/no adverse clinical ﬁndings DOW (1974)
a Values of ppm EGBE were corrected to mg/l based on 4.914 mg/m3 = 1 ppm.
b Unless otherwise noted, studies summarized were judged to have reliabilities of 1 or 2 using the scale and scoring system of Klimisch et al. (1997).
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of EGBE for up to 8 h. Seven male volunteers were exposed to
20 ppm of EGBE for 2 h while performing light work (Johanson,
1986). None of the exposed subjects in this latter study showed
any of the adverse effects related to EGBE exposures.
4.2. Case studies involving accidental and intentional ingestions of
EGBE
Reported cases of acute human poisonings with EGBE are rare
and generally involve either accidental ingestion in pediatric cases
or intentional ingestions in adults (Udden, 1996; Gualtieri et al.,
2003; Hung et al., 2010). Dean and Krenzelok (1991) reviewed 24
pediatric poisoning cases reported to the Pittsburgh Poison Center
(PPC) during a ﬁve month period from December of 1990 to April of
1991. These all involved glass or window cleaners containing EGBE
at concentrations ranging from 0.5% to 9.9%. The ages of the chil-
dren involved ranged from 7 months to 9 years. All incidents were
reported to the PPC within 5 min of the actual exposures. The esti-
mated quantities ingested ranged from 5 to 300 ml and all children
were reported to be asymptomatic immediately following the
ingestions. In the single greatest exposure among this group, a
2 year old was reported to have swallowed 300 ml of an 8%
EGBE-containing glass cleaner representing approximately 24 ml
of EGBE. In this latter case, the child underwent gastric lavage
and was hospitalized for 24 h. Evidence of the toxicity of EGBE,
as expressed in animals, and including hemolysis, central nervous
system depression, metabolic acidosis and renal compromise were
completely absent in these pediatric cases. In 22 of the reported 24
cases from this study, the patients were treated at home with sim-
ple dilution. All cases remained asymptomatic throughout an addi-
tional 48 h of telephone follow-up.
Summarized in Table 5 are a number of reported cases of inten-
tional ingestion by adults of large amounts of EGBE-containing
products. Reviews of these cases have been previously published
(Udden, 1996; Gualtieri et al., 2003; Hung et al., 2010). Severe met-
abolic acidosis and coma are consistently reported in these poison-ing cases. All patients required aggressive support with
administration of ﬂuids and mechanical ventilation. However, it
is important to note that in all reported cases, patients recovered
fully without subsequent symptomology. In those reported cases
for which blood levels of BAA were measured, concentrations typ-
ically peaked at 2 days or after with little still present by 3 days.
Maximum concentrations of BAA ranged as high as 3.64 mM (Ta-
ble 5) and were generally in excess of levels that cause hemolysis
in blood from sensitive species (Ghanayem and Sullivan, 1993), but
well below a concentration of 10 mM, a level reported to show only
the most minimal hemolytic effects in human blood (Udden, 2002).
In all but two of the cases listed in Table 5 (Gijsenbergh et al.,
1989; Bauer et al., 1992), hemodialysis was employed to remove
un-metabolized EGBE. In these reports there was no clear evidence
for hemolysis as seen in sensitive laboratory species. In reports by
Bauer et al. (1992) and Hung et al. (2010), non-hemolytic anemia
was attributed to hemodilution as a result of hemodialysis. Other
reported effects included renal insufﬁciency, thrombocytopenia
and disseminated intravascular coagulation. As discussed by Ud-
den (1996), these other effects reported were most likely not di-
rectly related to hemolysis. However, the exact etiology of these
latter effects in certain human poisoning cases cannot be explained
based on the limited data available. It can be concluded from these
adult poisoning cases that EGBE is generally of a low order of acute
toxicity in humans. High doses of EGBE in humans do not cause the
characteristic hemolytic effects which have been shown to be crit-
ical for the acute toxicity expressed in rats, mice and rabbits.5. Acute toxicity mode of action for EGBE
5.1. In vivo determinants of the hemolytic response to EGBE
Intravascular hemolysis is the major effect reported in acute
toxicity studies in rats, mice and rabbits following EGBE adminis-
tration. Both a dose- and concentration-dependent hemolytic ane-
mia develops in rats following the administration of a single dose
Table 5
Case reports of human adult EGBE ingestion.
Reports Age
(years)
Sex Amount
ingested (g)
Blood BAA
(mM)
Hemoglobin level
(g/dL)
Additional observations
Rambourg-Schepens
et al. (1988)
50 F 50–60 2.2a (Day 2) 9.7 Hemoglobinuria
Gijsenbergh et al.
(1989)
23 F 25–30 0.4a (Day 2) 8–9 Hematuria
Bauer et al. (1992) 45 M 45 N/A 9.1 Non-hemolytic anemia; Thrombocytopenia; adult respiratory distress
syndrome (ARDS); renal insufﬁciency
Litovitz et al. (1991) 87 F Unknown N/A Unknown Disseminated intravascular coagulation
Gualtieri et al. (1995,
2003)
18 M 80–100 3.64 and 2.07b
(Day 2)
Unknown Profound metabolic acidosis; CNS depression; no evidence of
hemolytic anemia
Hung et al. (2010) 53 M 150–250 ml N/A 13.1–10.7 (3 h post-
admission)
Metabolic acidosis; no red cell dysmorphology or evidence of
hemolysis
a Estimate taken from a graphical representation of the results and corrected to mM concentration units based on an average serum concentration of 0.7 mg/dl creatinine
for females.
b Intentional ingestions on 2 separate occasions.
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urinary metabolite of EGBE, 2-butoxyacetic acid (BAA), was origi-
nally conﬁrmed to be the proximate hemolytic agent by Carpenter
et al. (1956). In human poisoning cases as discussed above, meta-
bolic acidosis is a commonly reported effect (Udden, 1996). Lactic
acidosis is also observed in most of these cases of EGBE ingestion
and it has been suggested that this may be a consequence of EGBE
metabolism in humans (Hung et al., 2010). Thus, a combination of
lactate production and BAA lead to the metabolic acidosis observed
in human poisonings (Gijsenbergh et al., 1989). Other factors such
as dialysis and hypotension may also contribute to the observed
consequences of human ingestions (Udden, 1996; Hung et al.,
2010). There are no comparable reports or studies of EGBE-induced
acidosis in laboratory animals that can be used as a direct compar-
ison to the effects seen in humans. At least in the case of the rat, the
most extensively studied laboratory species, there is evidence that
metabolic acidosis may be of much less consequence. In particular,
this species more rapidly metabolizes and eliminates EGBE and its
metabolites than do humans (Corley, 1996). Also, the tolerance in-
duced in rats following either repeated or single sub-lethal doses of
EGBE strongly argues for hemolysis as the primary toxicological re-
sponse in this species, with other factors of only secondary impor-
tance (Ghanayem et al., 1992; Sivarao and Mehendale, 1995).
A number of detailed hematological investigations of EGBE tox-
icity have been conducted in the Fischer strain of rat. In a sub-acute
oral toxicity study reported by Grant et al. (1985), four to ﬁve week
old male F344 rats received 500 or 100 mg/kg EGBE for 4 days.
These rats displayed decreased erythrocyte counts; increased rela-
tive weights of spleen, liver and kidneys; thymic atrophy; and lym-
phocytopenia. Microscopic examination of blood in this study was
consistent with intravascular hemolysis and revealed increased
numbers of circulating nucleated erythrocytes (normoblasts), pro-
nounced anisocytosis, polychromasia and the presence of Howell
Jolly bodies. All of these effects resolved within a 22-day recovery
period, with the exception of relative weights of liver and spleen,
which remained slightly raised. In studies by Ghanayem et al.
(1987b), groups of adult (9–13 week) or young (4–5 week) male
F344 rats were dosed EGBE by single gavage treatment at 32, 63,
125, 250 or 500 mg/kg bw. Signiﬁcant decreases in circulating
erythrocytes, hemoglobin concentrations, and hematocrit were
seen in adult rats at doses of 125 mg/kg bw and above but in young
rats only at 250 mg/kg bw or higher. The greatest changes occurred
within 4–24 h. The onset of hemoglobinuria followed the decline in
plasma hemoglobin levels and was again more pronounced for
adult rats. Hematological changes were mostly resolved by 48 h.
Histopathological changes in the liver including focal disseminated
coagulative necrosis of hepatocytes and evidence of hemoglobinphagocytosis by Kupfer cells and hepatocytes were present at the
two highest dose levels in adult rats but were absent in young rats.
In concurrent metabolism studies, young rats excreted a greater
proportion of the dose as carbon dioxide or urinary metabolites
(Ghanayem et al., 1987b). It was proposed that the greater suscep-
tibility of the older rats to the hemolytic toxicity of EGBE may be
due, at least in part, to a greater proportion of BAA formed and
to a depressed urinary excretion.
In a comparison of the in vivo hemolytic toxicity between rats
(sensitive) and guinea pigs (insensitive), both species were given
a sub-lethal gavage dose of EGBE at 250 mg/kg bw and blood
parameters measured for up to 25 h (Ghanayem and Sullivan,
1993). As expected, rats showed signiﬁcant declines in MCV,
HCT, HGB and erythrocyte counts, associated with hemolysis. In
guinea pigs, no changes in any of these parameters were recorded.
Thus, sensitive laboratory species such as rats, when exposed to
acutely toxic doses of EGBE, display a number of responses second-
ary to hemolysis and including enlarged kidneys, blood in the blad-
der, bloody urine, and splenic lesions. In contrast, guinea pigs
display less sensitivity to the acute toxicity of EGBE than either
rats, mice or rabbits and do not display the adverse pathological ef-
fects associated with hemolysis as seen in the other sensitive
species.
Carpenter et al. (1956) ﬁrst identiﬁed BAA as the metabolite
responsible for the hemolytic toxicity of EGBE by incubating the
acid with blood from a variety of animal species and humans. In
these studies, blood from rats, mice, and rabbits was more rapidly
hemolysed than blood from monkeys, dogs, humans or guinea pigs
when incubated at 37 C in a 0.1% saline solution of sodium but-
oxyacetate (BAA). Also, inhalation exposures of rats, mice and rab-
bits led to increased osmotic fragility of erythrocytes while no
similar effects were reported in monkeys, dogs, humans or guinea
pigs, thus conﬁrming the relevance of the in vitro responses
(Carpenter et al., 1956).
Ghanayem and Sullivan (1993) have assessed the in vitro hemo-
lytic response of BAA in blood from a variety of species including
rats, mice, hamsters, rabbits, guinea pigs, dogs, cats, pigs, baboons
and humans. In these studies, blood collected with 7.5% EDTA as
anticoagulant was treated with 1.0 or 2.0 mM BAA concentrations.
These concentrations were selected because previous in vivo stud-
ies indicated these blood levels were found to cause intermediate
levels of toxicity (Ghanayem, 1989). Blood was incubated at
37 C and samples collected at 1, 2 and 4 h and spun hematocrits
obtained (HCT). Complete blood counts were obtained using an
automated hematology analyzer and included the following: white
blood cell counts, platelet counts, red blood cell (RBC) counts,
mean cell volume (MCV), mean corpuscular hemoglobin (MCH)
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from rodents, as represented by rats, mice and hamsters, displayed
a time and concentration dependent increase in HCT and MCV
when incubated with BAA, with more than a 45% increase above
the corresponding control in MCV at 2 h and 6% decrease in RBC
counts in rats and mice. At the higher concentration, RBC counts
decreased 30% below control levels by 4 h. In hamsters, MCV in-
creased greater than 15% and 35% above control levels at 1 or
2 mM BAA for 4 h, respectively. Although signiﬁcant swelling oc-
curred, no hemolysis of hamster blood was observed. Blood from
rabbits incubated at 2 mM displayed greater than 20% increases
in MCV above control levels at 2 h with a further increase to 39%
by 4 h. Despite this extensive swelling of the RBCs, there was no
signiﬁcant change in RBC counts or hemoglobin concentrations
suggesting hemolysis had not occurred under these in vitro condi-
tions. The time- and concentration-dependent swelling of the
erythrocytes of sensitive species leading to increased HCT and
MCV is the effect most relevant to in vivo hemolysis. Such changes
lead to decreased deformability of the erythrocytes, decreased abil-
ity to pass through small capillaries and subsequent removal of
these damaged cells from circulation by the spleen.
Blood samples from a number of species tested by Ghanayem
and Sullivan (1993) were insensitive to the hemolytic effects of
BAA. Thus, blood from the guinea pig (Cavia procellus) was essen-
tially unaffected by incubations with 1 or 2 mM BAA for up to
4 h. Blood from two primate species were also assayed in these
studies. Incubations of blood collected from 4 healthy male adult
humans with 2 mM BAA for up to 4 h caused only slight and statis-
tically insigniﬁcant changes in MCV and HCT. In the case of blood
from the yellow baboon, MCV increased in a time- and concentra-
tion-dependent manner to nearly 35% above control values after
4 h with 2 mM BAA. HCT in this species increased in a parallel fash-
ion with MCV and hemolysis was signiﬁcant at either the 1 or
2 mM BAA concentration by 4 h. The contrasting results from ba-
boons and humans, both of the order primate, suggest the hemo-
lytic sensitivity to BAA cannot be predicted solely based on order
or class of mammal.
Udden (1996) has studied the effects of BAA on human erythro-
cytes from young (aged 31–56 years) versus old (aged 64–
79 years) adults as well as blood from patients with hemolytic dis-
orders. The increased toxicity of EGBE in older rats has been attrib-
uted to older erythrocytes (Ghanayem et al., 1987b). Incubation of
erythrocytes from young versus old humans with 2.0 mM BAA pro-
duced no signiﬁcant hemolysis. Similarly, erythrocytes from pa-
tients with sickle cell disease and those with hereditary
spherocytosis were unaffected. It is notable that erythrocyte swell-
ing with loss of the discocyte morphology is characteristic of BAA-
induced changes in rats and this change is also a characteristic of
hereditary spherocytosis.
Although when incubated at concentrations of 2.0 mM and be-
low no signiﬁcant effects on human erythrocytes have been ob-
served, sub-hemolytic effects have been reported when human
erythrocytes are incubated at high BAA concentrations (Udden,
2002). Incubations of human erythrocytes at concentrations
7.5 mM and 10 mM for 1–4 h resulted in decreased deformability,
as measured by ﬁltration, and slight but signiﬁcant increases in
MCV at the 10 mM concentration. Similar effects were observed
when rat erythrocytes were incubated at 0.1 mM for 4 h. Thus, at
10 mM BAA, a 40% increase in ﬁltration pressure was seen for hu-
man erythrocytes compared with a 64% increase in ﬁltration pres-
sure for rat erythrocytes incubated at a 100-fold lower
concentration of 0.1 mM. Thus, a minimum 100-fold lower sensi-
tivity of human versus rat erythrocytes was seen in this study.
Starek et al. (2008) have reported similar but less pronounced
differences in the hemolytic effects of BAA between rat and human
erythrocytes. Washed erythrocytes from healthy human donors ormale Wistar rats were incubated in 10 mM Tris buffer for up to 3 h
with BAA concentrations ranging from 6.0 to 18.0 mM (humans) or
1.0–5.5 (rats). EC50 values for changes in red blood cell counts
(RBC), packed cell volumes (PCV) and mean corpuscular volumes
(MCV) were then obtained. It is important to note that the EC50 va-
lue for PCV changes with BAA was 13.1 mM, but a similar EC50 va-
lue could not be determined for MCV changes since these were not
large enough to allow calculation of this value. There are several
reasons why this work does not lend itself to direct comparison
with the greater body of work reported on the comparative effects
of hemolysis by EGBE in different species. In particular, no discus-
sion is given by these authors to the possible effects of the very
high concentrations employed in these studies. A possible explana-
tion for the effects reported is that cell damage and hemolysis,
resulting in lowered RBC values, occurred due to uncontrolled
and lowered pH; with these effects seen without the attendant cell
swelling and the normally observed changes in PCV and MCV.
These results also contradict the ﬁndings of other workers includ-
ing Udden (2002) and Ghanayem (1989), who report only the most
minimal and non-speciﬁc effects on human erythrocytes at 8.0 or
10 mM in vitro concentrations, and the work of Bartnik et al.
(1987), who reported no hemolysis of human red blood cells incu-
bated for 3 h with 15 mM BAA. Such high and physiologically irrel-
evant concentrations are considered of little or no use in the
present human hazard assessment of EGBE.6. Utilizing a weight of evidence approach to classify for acute
toxicity
The application of expert judgment using a weight of evidence
approach is a key feature of the hazard classiﬁcation of chemicals
under GHS (Morita and Morikawa, 2011; Hamilton et al., 2006).
However, weight of evidence is a somewhat nebulous concept that
does not have a set of well-deﬁned tools and procedures for its
implementation (Morita and Morikawa, 2011). In the ideal situa-
tion, all reliable scientiﬁc data relevant to the endpoint of concern
undergoes expert review and subsequently is weighted to allow a
ﬁnal hazard classiﬁcation. However, GHS is a Globally Harmonized
System that is applied among many countries and regions of the
world and with differences in the procedure used for its implemen-
tation. This often leads to discrepancies in the hazard classiﬁcation
of substances (Morita and Morikawa, 2011; OECD, 2010). This re-
view is an attempt to perform a deﬁnitive assessment based on
the hazard to humans that can be used as a basis to derive an acute
toxicity classiﬁcation for EGBE where ever GHS is implemented.
The categorization of acute hazard under GHS requires acute
toxicity estimation (ATE) for placement into one of ﬁve hazard cat-
egories (Table 1). These categories are deﬁned by various sharp
cut-off values and the information used for the ﬁnal category
assignments is most often derived from inherently variable acute
toxicity data derived from animal studies. The problems associated
with this method are clearly illustrated in a recent publication by
Hoffmann et al. (2010) in which a large dataset of acute oral toxic-
ity data from experimental animals was compared for a total of 73
reference chemicals. Reliable studies, as deﬁned by a Klimisch
score of 1, ‘‘reliable’’, or 2, ‘‘reliable with restrictions’’, were scarce
with data often available from studies over several decades old.
Statistical analyses revealed that only 50% of the substances
would be unequivocally assigned to a single classiﬁcation category
(under GHS or EU categories); 40% would unequivocally be clas-
siﬁed within two adjacent categories; and 10% would have LD50
ranges sufﬁciently large to span three or more classiﬁcation
categories.
In the current report, data from acute toxicity studies in exper-
imental animals along with information from mode of action stud-
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toxicity of EGBE. In sensitive rodent species, hemolysis of erythro-
cytes caused by the major metabolite of EGBE, BAA, has been
shown to be responsible for the acute effects and mortality ob-
served with this solvent (Carpenter et al., 1956). The central role
of BAA as the proximate hemolytic agent in sensitive species has
been further conﬁrmed through in vivo studies employing meta-
bolic inhibitors such as pyrazole and cyanamide, to block metabo-
lism to the acid through alcohol and aldehyde dehydrogenases,
respectively (Ghanayem et al., 1987a). Incubation of erythrocytes
isolated from a variety of animal species with BAA indicates a large
variation in the sensitivity to this hemolytic agent, with erythro-
cyte swelling and hemolysis occurring most readily and at low
concentrations in blood from rats, mice and rabbits but absent in
blood from humans and guinea pigs (Carpenter et al., 1956; Ghana-
yem and Sullivan, 1993). Similar incubations of erythrocytes iso-
lated from healthy young or old humans or from patients
suffering from congenital hemolytic disorders produced no signif-
icant hemolysis or morphological changes as seen in erythrocytes
from the rat (Carpenter et al., 1956; Udden and Patton, 1994; Ud-
den, 1996, 2000, 2002). In fact, more than 100-fold higher concen-
trations of BAA are required to produce even a minimal pre-
hemolytic in human versus rat erythrocytes (Udden, 2002).
In more recent guideline studies conducted in guinea pigs, EGBE
displayed a low acute toxicity following oral, dermal or inhalation
exposures (Gingell et al., 1998). An acute oral LD50 value of
1414 mg/kg bw (males and females) was reported in these studies
and animals dying prior to study termination demonstrated
pathology suggesting EGBE was a gastrointestinal irritant (Shep-
ard, 1994a). There was no evidence of hemolytic toxicity in this
acute oral study. Dermal administration under occlusive wrap at
a limit dose of 2000 mg/kg bw produced no mortality or other
signs of toxicity in the guinea pig (Shepard, 1994b). Inhalation
exposures (1 h) at maximum achievable vapor concentrations of
633 (males) and 691 ppm (females) produced no mortalities or
clinical signs of toxicity (DOW, 1994).
Perhaps the most convincing evidence of the low acute toxicity
of EGBE in humans comes from accidental ingestions reported in
pediatric cases or intentional ingestions in adults (Dean and Krenz-
elok, 1991; Udden, 1996; Gualtieri et al., 2003; Hung et al., 2010).
In 24 pediatric poisoning cases reviewed, only two required hospi-
talizations with the remainder treated at home with palliative care
(Dean and Krenzelok, 1991). In a number of adult poisoning cases
severe metabolic acidosis was consistently observed. However, in
all reported poisoning cases the patients survived and recovered
without subsequent symptomology. In two exceptional cases, esti-
mated quantities consumed of EGBE were 80–100 g (Gualtieri
et al., 2003) or 150–250 ml (Hung et al., 2010). In one case, blood
concentrations of BAA as high as 3.64 mM were reported but with
no evidence of hemolytic anemia (Gualtieri et al., 2003).7. Conclusions
Acute oral, dermal and inhalation toxicity values derived from
rats and rabbits often serve as the basis for acute toxicity classiﬁ-
cations. Both of these species show increased sensitivities to the
intravascular hemolysis caused by BAA, the hemolytic metabolite
of EGBE. This increased sensitivity in turn leads to an overly con-
servative acute hazard classiﬁcation for this chemical. An extensive
body of work over many decades and from a number of different
investigators has clearly shown that the effects on the erythrocytes
of sensitive species such as the rat and rabbit are not representa-
tive of the human response to this chemical and that the guineapig is a more appropriate surrogate species for the acute hazard
classiﬁcation of EGBE.
7.1. Weight of evidence approach to assignment of an acute oral
toxicity hazard classiﬁcation for EGBE under GHS
Although varying considerable within and among species, the
majority of the LD50 values presented in Table 2 are consistent with
a Category 4 acute oral toxicity classiﬁcation under GHS. Speciﬁ-
cally, all values are above the upper cut-off value of 300 mg/kg bw
for the Category 3 classiﬁcation, while some few of the reported
LD50 values fall near or slightly above the cut-off for the Category
4 classiﬁcation (Table 1), i.e. into Category 5 (or no classiﬁcation
under the EU CLP regulation).
7.2. Weight of evidence approach to assignment of an acute dermal
toxicity hazard classiﬁcation for EGBE under GHS
In both the rat and rabbit, signs of the acute systemic toxicity of
EGBE are evident and are consistent with exposures by other
routes. As in the case of acute oral exposures, there is compelling
evidence to suggest the rabbit is the most sensitive of the experi-
mental animals when tested dermally. In the rat, clinical and path-
ological signs of hemolysis are evident generally at or above acute
dermal toxicity LD50 values of 2000 mg/kg bw and are more pro-
nounced following occlusive exposures. Similar effects are ob-
served in the rabbit but at acute dermal toxicity LD50 values
ranging from 435 to 1060 mg/kg bw (occlusive). Given the in-
creased sensitivity of both the rat and rabbit to the hemolytic ef-
fects of EGBE, an effect that is not representative of the situation
in humans, the guinea pig is considered the most representative
species for assigning an acute dermal toxicity hazard for human
exposures (LD50 > 2000 mg/kg bw). Based on reliable and more re-
cent studies of the acute dermal toxicity of EGBE in the guinea pig,
as well as supportive mechanistic and well-documented human
exposure data, a Category 5 acute dermal toxicity classiﬁcation un-
der GHS (or no classiﬁcation under the EU CLP regulation) is the
most appropriate outcome for EGBE.
7.3. Weight of evidence approach to assignment of an acute inhalation
toxicity hazard classiﬁcation for EGBE under GHS
In the rat and rabbit, two species sensitive to the hemolytic tox-
icity of EGBE, reported acute inhalation toxicity LC50 values ranged
from approximately 2 mg/l to values exceeding the theoretical cal-
culated maximum achievable vapor concentration of EGBE
(3.9 mg/l). Reported clinical and pathological effects from these
studies conﬁrm an acute hemolytic response in these species. In
contrast, dogs exposed for up to 7 h at 2.0 mg/l were unaffected.
Similarly, guinea pigs exposed at either 2.0 mg/l for 7 h or at max-
imum achievable vapor concentrations for 1 h were unaffected. Gi-
ven the increased sensitivity of both the rat and rabbit to the
hemolytic effects of EGBE, the guinea pig is considered the most
representative species for assigning an acute inhalation toxicity
hazard for human exposures. Based on reliable studies of the acute
inhalation toxicity of EGBE in the guinea pig, as well as supportive
mechanistic and well-documented human exposure data, no clas-
siﬁcation of EGBE for acute inhalation toxicity under GHS is
warranted.
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